Control vs Alzheimer's Disease: tau-p217 (Plasma and Serum)
Recently-developed assays target tau phosphorylated at threonine 217 (tau-p217). In a meta-analysis of two studies, levels of plasma tau-p217 showed a non-significant trend towards elevation in Alzheimer’s disease, compared with control subjects: Levels of plasma tau-p217 in controls were only about one-fourth those in individuals with Alzheimer's disease (effect size = 0.258, p = 0.082). Additional data are needed to confirm—or refute—this finding. Tau-p217, in plasma or CSF, has been reported to discriminate Alzheimer’s disease from other dementias better than does tau-p181 (see 10 Apr 2020 and 29 Jul 2020 news).